Spots Global Cancer Trial Database for antiemetics
Every month we try and update this database with for antiemetics cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer | NCT01046461 | Solid Tumour Postoperative N... | Ramosetron, Apr... | 18 Years - 75 Years | Hallym University Medical Center | |
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen | NCT01490060 | Sarcoma Chemotherapy-in... Effects of Chem... Adverse Effects... | Fosaprepitant Dexamethasone 5HT3 receptor a... Ifosfamide-base... Doxorubicin Mesna Ifosfamide Vincristine | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas | NCT00401388 | Chondrosarcomas Alveolar Soft P... Extra Skeletal ... | Perifosine Loperamide Allopurinol Antiemetics | 13 Years - | AEterna Zentaris | |
Comparison of Dexamethasone Alone vs in Combination With Pericardium 6 (P6) Electrical Stimulation or Granisetron in the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Breast Cancer Surgery | NCT05408676 | Mammary Cancer PONV | electric stimul... | 18 Years - 64 Years | Fudan University | |
Fosaprepitant , Tropisetron and Olanzapine for the Prevention of Nausea and Vomiting in Patients With Breast Cancer | NCT05242874 | Chemotherapy-in... | Fosaprepitant ,... Fosaprepitant ,... | 18 Years - 70 Years | Henan Cancer Hospital | |
Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer. | NCT03606369 | Breast Neoplasm Antineoplastic ... Antiemetics Quality of Life | Palonosetron Ondansetron | 18 Years - | Instituto Nacional de Cancerologia de Mexico | |
A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC) | NCT01636947 | Nausea Vomiting | Aprepitant Aprepitant Plac... Ondansetron Dexamethasone Ondansetron Pla... Rescue Therapy ... | 21 Years - | Merck Sharp & Dohme LLC |